TOKYO (dpa-AFX) - Japan's Takeda Pharmaceutical Co. Ltd. (TAK, TKPHF.PK) reported that its net profit for the nine-month period ended December 31, 2022 increased by 18.4% to 285.9 billion yen from
08.06.2022 - Globalization has been a key priority for the Company over the past two yearsThree additional market agreements now signed and executed:- Labatec Pharma SA: Switzerland, Middle East & North Africa (MENA) countries- Pharmbio Korea Inc.: South Korea- . Seite 1
/PRNewswire/ DelveInsight s "Cerebral Palsy Market" report provides a thorough comprehension of the Cerebral Palsy historical and forecasted epidemiology.